ProKidney Corp.

NASDAQ:PROK

Biotechnology

Healthcare
$1.04 +0.86%

+$0.02 today

Market cap
$349.70M
Beta
1.70
P/E (TTM)
-3.3
EPS (TTM)
-$0.53
52W Low $0.54High $7.13

Volume 1.80M

Average 0.96M

PROK Intangible Assets

Identifiable non-physical assets such as patents, trademarks, licenses, and customer relationships.

ProKidney Corp.NASDAQ: PROK

Intangible Assets · Q1 FY2026 · quarter ended Mar 2026

Intangible assets remains negative

Q1 FY2026 intangible assets was $0, compared with $0 a year earlier.

Context

  • Intangible assets amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Intangible assets increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Intangible Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Intangible Assets history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Intangible Assets vs competitors

How PROK compares with its peers on the latest reported figures

  • PROK's Mar 2026 intangible assets of $0 is the 2nd highest of the 7 companies compared; the peer median is $0.
  • Intangible assets amounts to 0.0% of total assets for PROK, versus a peer median of 0.0%.
PROK Competitors Peer median
Intangible Assets for PROK and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
TVTXTravere Therapeutics, Inc.Sep 2026$164.11M +51.0%+5.5%19.3%
PROKProKidney Corp.Mar 2026$0 ——0.0%
MAZEMaze Therapeutics, Inc.Mar 2026$0 ——0.0%
ARDXArdelyx, Inc.Mar 2026$0 ——0.0%
DMACDiaMedica Therapeutics Inc.Mar 2026$0 ——0.0%
MENSJyong Biotech Ltd. Ordinary SharesDec 2025$0 ——0.0%
UNCYUnicycive Therapeutics, Inc.Mar 2026$0 ——0.0%
Peer median (excluding PROK) $0+51.0%+5.5%0.0%

Competitors are the stored peer set for PROK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents20.56M490.25M60.65M99.12M108.54M
Short-term Investments00302.3M259.17M161.48M
Net Receivables001.38M2.45M1.13M
Inventory00000
Other Current Assets25K1.38M9K19.45M2.8M
Total Current Assets27.27M504.72M374.15M395.88M280.68M
Property, Plant & Equipment (Net)12.6M13.06M46.41M45.19M54.9M
Goodwill00000
Intangible Assets428K213K000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets00000
Total Non-current Assets13.03M13.28M46.41M45.19M54.9M
Total Assets40.3M518M420.55M441.07M335.57M
Account Payables2.83M3.04M5.1M3.63M940K
Short-term Debt00000
Tax Payables0278K1.47M682K1.07M
Deferred Revenue00000
Other Current Liabilities1.83M3.36M7.52M11.45M11.84M
Total Current Liabilities12.31M10.87M25.04M36.22M30.74M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities0278K568K748K1.07M
Total Non-current Liabilities1.07M2.18M4.18M3.22M4.04M
Total Liabilities13.38M13.06M29.22M39.44M34.78M
Common Stock188.43M24K23K29K30K
Retained Earnings(161.51M)(1.1B)(1.14B)(1.2B)(1.27B)
Accumulated OCI00130K130K56K
Other Stockholders Equity00000
Minority Interest01.6B1.49B1.4B1.31B
Total Equity26.92M504.94M391.34M401.64M300.79M
Total Debt1.33M2.4M4.41M3.24M4.04M
Net Debt(19.22M)(487.85M)(56.24M)(95.88M)(104.5M)

ProKidney Corp.

NASDAQ:PROK

Intrinsic Alpha fair value

Locked

Current Price

$1.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.